1-3 of 3
Daniel M. Sze, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Immunomodulatory Action of Thalidomide in Patients with Multiple Myeloma Involves a Clonal Expansion of Late-Differentiated Cytotoxic Effector Cells.

Ross D. Brown, PhD, Allan Murray, Daniel M. Sze, PhD, Andrew Spencer, MD, Phoebe Joy Ho, MD, John Gibson, MD, Douglas E. Joshua, MD
Journal: Blood
Blood (2005) 106 (11): 5108.
https://doi.org/10.1182/blood.V106.11.5108.5108
Published: 2005
Journal Articles

Gene Expression Profiles of the Clinically Significant "Late" Stage Expanded Cytotoxic T Cells in Myeloma.

Tetsuo Yamagishi, BSc, Warren Kaplan, PhD, Devanshi Seth, PhD, Shihong Yang, MMed, Xin An, PhD, Ross D. Brown, PhD, Joy Ho, MBBS, John Gibson, MBBS, Douglas E. Joshua, MBBS, Daniel M. Sze, PhD
Journal: Blood
Blood (2005) 106 (11): 3418.
https://doi.org/10.1182/blood.V106.11.3418.3418
Published: 2005
Journal Articles

Development of Retargeted CD38-Specific NK-92 Cell Line for Potential Anti-Myeloma Immunotherapy.

Shihong Yang, MMed, Xin An, PhD, Ross D. Brown, PhD, Joy Ho, PhD, John Gibson, PhD, Douglas E. Joshua, PhD, Winfried Wels, PhD, Daniel M. Sze, PhD
Journal: Blood
Blood (2005) 106 (11): 5104.
https://doi.org/10.1182/blood.V106.11.5104.5104
Published: 2005